Seeking Alpha

Tesaro slides as investors not impressed with data

  • Investors don't seem impressed with top-line data from two Phase 3 trials of Tesaro's (TSRO) NK-1 receptor antagonist rolapitant in chemotherapy-induced nausea and vomiting.
  • The studies met their primary endpoints of CR (no vomiting and no use of rescue medication) in the delayed phase.
  • However, neither trial hit statistical significance in the acute and overall phases (secondary endpoints).
  • The company says preparations are ongoing for an NDA submission in mid-2014. (PR)
  • TSRO -14% premarket.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: